English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduCombining the KRAS G12C inhibitor adagrasib with the anti-EGFR antibody cetuximab demonstrated promising anti-tumor effects in patients with KRAS G12C-mutated metastatic colorectal cancer (CRC), according to pooled results from the Phase I/II KRYSTAL-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.
Tag: EGFR inhibitor
MD Anderson EGFR Classification licensed by BostonGene and Tempus to provide new insight on atypical mutations in lung cancer
MD Anderson announced licensing agreements with BostonGene and Tempus for the MD Anderson EGFR Classification, which organizes EGFR mutations into subgroups that may guide clinical decision-making.